WO2003037225A1 - Lentilles intraoculaires munies de bords angules pour prevenir une opacification capsulaire posterieure - Google Patents
Lentilles intraoculaires munies de bords angules pour prevenir une opacification capsulaire posterieure Download PDFInfo
- Publication number
- WO2003037225A1 WO2003037225A1 PCT/FR2002/003754 FR0203754W WO03037225A1 WO 2003037225 A1 WO2003037225 A1 WO 2003037225A1 FR 0203754 W FR0203754 W FR 0203754W WO 03037225 A1 WO03037225 A1 WO 03037225A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- intraocular lens
- peripheral edge
- posterior
- lens according
- haptic
- Prior art date
Links
- 230000002093 peripheral effect Effects 0.000 claims abstract description 27
- 230000001154 acute effect Effects 0.000 claims abstract description 16
- 230000003287 optical effect Effects 0.000 claims description 47
- 239000000463 material Substances 0.000 claims description 39
- 239000002775 capsule Substances 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 230000005012 migration Effects 0.000 claims description 6
- 238000013508 migration Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920001971 elastomer Polymers 0.000 claims description 2
- 239000000806 elastomer Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- -1 polysiloxane Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 238000003754 machining Methods 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 description 10
- 206010002945 Aphakia Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000007943 implant Substances 0.000 description 7
- 210000004087 cornea Anatomy 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 210000002159 anterior chamber Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 208000008516 Capsule Opacification Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000009416 shuttering Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
- A61F2/16—Intraocular lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2002/1681—Intraocular lenses having supporting structure for lens, e.g. haptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2002/1681—Intraocular lenses having supporting structure for lens, e.g. haptics
- A61F2002/1683—Intraocular lenses having supporting structure for lens, e.g. haptics having filiform haptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2002/16965—Lens includes ultraviolet absorber
- A61F2002/1699—Additional features not otherwise provided for
Definitions
- Intraocular lenses with angled edges to prevent posterior capsular clouding Intraocular lenses with angled edges to prevent posterior capsular clouding.
- the present invention relates to intraocular lenses (IOLs) and a method of making and using them. More particularly, the present invention relates to IOLs with angled edges to prevent posterior capsular clouding in aphakic eyes from which the natural lens of the eye has been surgically removed.
- IOLs intraocular lenses
- Cataract extraction is one of the most commonly performed operations in the United States and around the world.
- the eye lens is located inside a so-called capsular bag or lens capsule located in the posterior chamber of the eye.
- an incision is made in the limbus of the eye in order to introduce a surgical instrument into the anterior chamber of the eye.
- a capsulo-hexis procedure is followed in which a portion of an anterior membrane of the lens capsule adjacent to the iris of the eye is extracted using a cutting surgical instrument to provide direct access to the lens with cataracts from the anterior chamber.
- the lens with cataracts is then extracted using various known methods, including phacoemulsification.
- Phacoemulsification is a procedure that involves applying ultrasonic energy to the lens with cataracts to break the lens into small pieces that can be aspirated from the lens capsule. With the exception of the portion of the anterior membrane of the lens capsule removed during the capsulo-hexis procedure, the lens capsule remains essentially intact for the duration of an extracapsular cataract extraction. Following the extraction of the lens affected by cataracts, an implant artificial intraocular lens (IOL), as discussed in more detail below, is typically implanted within the lens capsule to mimic the refractive function of the extracted natural lens. Implants of the IOL have been used for years in the aphakic eyes from which the natural lens of the eye has been extracted.
- IOL intraocular lens
- IOLs Many different designs of the IOL have been developed in the past few years and have been used successfully in the eyes of the scalp. At present, successful IOL designs mainly include an optical portion with its supports, called haptics, connected to and surrounding at least part of the optical portion.
- the haptic portions of an IOL are designed to support the optical portion of the IOL in the lens capsule, the anterior chamber, or the posterior chamber of an eye.
- Commercially successful IOLs have been made from a variety of biocompatible materials, ranging from stiffer materials such as polymethylmethacrylate (PMMA) to more flexible materials capable of being folded or compressed such as silicones and certain acrylics.
- PMMA polymethylmethacrylate
- Haptic portions of the IOLs were formed separately from the optical portion and then subsequently connected to this portion by processes such as heat, physical stapling and / or chemical bonding. LIOs with haptics attached in this way are commonly called “multi-room” LIOs. IOLs are also commonly produced with haptics formed as an integral part of the optical portion in what is commonly called “monoblock” IOLs.
- Softer, softer IOLs have grown in popularity in recent years due to their ability to compress, bend, roll or otherwise deform. These softer IOLs can be deformed before their insertion through an incision in the cornea of the eye. Following the insertion of the IOL in the eye, the IOL returns to its original form before deformation due to the memory characteristics of soft matter.
- Softer, more flexible IOLs such as those just described can be implanted in one eye through an incision which is much smaller, i.e. 2.8 to 3.2 mm, than that necessary for more rigid IOLs, i.e. 4.8 to 6.0 mm.
- a larger incision is necessary for more rigid IOLs because the lens must be inserted through an incision in the cornea slightly larger than that of the diameter of the optical portion of the rigid IOL.
- stiffer IOLs have become less popular in the market as it has been found that larger incisions are associated with an increased incidence of post-operative complications such as induced astigmatism.
- OCP posterior capsular clouding
- Intraocular lenses (IOLs) made in accordance with the present invention have an optical portion having an outer peripheral edge and two or more, but preferably two, three or four equidistant haptic elements to support the optical portion in a patient's eye.
- each of the haptic elements is of similar shape to obtain a "helix" effect to facilitate the implantation, rotation and centering of the IOL. The helix effect also improves accessibility inside the capsule for cleaning cortical remains.
- Each of the haptic elements has an internal portion and an external portion. The internal portion of each haptic element comprises an enlarged fixing portion permanently connected to the external peripheral edge of the optical portion.
- each haptic element includes a rounded free end.
- Each haptic element comprises an elongated central portion in the form of an arc which extends between the enlarged fixing portion and the rounded free end. From the enlarged fixing portion and all along the elongated central portion in the form of an arc, the dimensions of the haptic element may be stable or may vary. The particular angular shape of the haptic elements allows the rotation of the IOLs and prevents posterior capsular clouding.
- an object of the present invention is to provide intraocular lenses for use in aphakic eyes.
- Another object of the present invention is to provide intraocular lenses for use in aphakic eyes capable of being implanted through a small incision.
- Another object of the present invention is to provide intraocular lenses which prevent posterior capsular clouding.
- Another object of the present invention is to provide intraocular lenses which allow greater ease of implantation, rotation and centering of said lenses.
- Another object of the present invention is to provide intraocular lenses which are biocompatible for use in aphakic eyes.
- Yet another object of the present invention is to provide intraocular lenses which are resistant to decentering inside the eyes.
- Figure 1 is a schematic representation of the interior of a human eye comprising a natural lens and a refractive IOL implanted in the lens capsule of the eye;
- Figure 2 is a plan view of an IOL with two haptics made in accordance with the present invention;
- Figure 3 is a side view of the IOL of Figure 2;
- Figure 4 is a cross-sectional view of an optical portion of the IOL of Figure 2 taken along line 4-4;
- Figure 5 is a cross-sectional view of a haptic element of the IOL of Figure 2 taken along line 5-5;
- Figure 6 is a cross-sectional view of a haptic element of the IOL of Figure 2 taken along line 6-6;
- Figure 7 is a cross-sectional view of a haptic element of the IOL of Figure 2 taken along line 7-7;
- Figure 8 is a plan view of another embodiment of an IOL with two haptics made in accordance with the present invention.
- Figure 9 is a side view of the IOL of Figure 8.
- Figure 10 is a cross-sectional view of an otic part of the IOL of Figure 8 taken along line 10-10;
- Figure 11 is a cross-sectional view of a haptic element of the IOL of Figure 8 taken along line 11-11;
- Figure 12 is a cross-sectional view of a haptic element of the IOL of Figure 8 taken along the line 12-12;
- Figure 13 is a cross-sectional view of a haptic element of the IOL of Figure 8 taken along line 13-13;
- Figure 14 is a plan view of another embodiment of an IOL with three haptics made in accordance with the present invention.
- Figure 15 is a side view of the IOL of Figure 14;
- Figure 16 is a cross-sectional view of an otic part of the IOL of Figure 14 taken along line 16-16;
- Figure 17 is a cross-sectional view of a haptic element of the IOL of Figure 14 taken along line 17-17;
- Figure 18 is a cross-sectional view of a haptic element of the IOL of Figure 14 taken along line 18-18;
- Figure 19 is a cross-sectional view of a haptic element of the IOL of Figure 14 taken along line 19-19.
- FIG. 1 is a schematic view of an eye 10 showing the structures which are related to implantation of intraocular lenses (IOL) 12 according to the present invention.
- the eye 10 comprises an optically clear cornea 14 and an iris 16.
- a lens capsule 18 and a retina 20 are placed behind the iris 16 of the eye 10.
- the eye 10 also comprises an anterior chamber 22 situated in front of the iris 16 and a posterior chamber 24 located between the iris 16 and the lens capsule 18.
- the IOL 12 is preferably implanted in the lens capsule 18 of the aphakic eye. When used in aphakic eyes, IOLs 12 are used to replace diseased natural lenses that have been surgically removed, for example after cataract surgery.
- the eye 10 also includes an optical axis OA-OA which is an imaginary line passing through the center optic 28 of the anterior surface 30 and the posterior surface 32 of the lens capsule 18.
- the optical axis OA-OA in the human eye 10 is generally perpendicular to a portion of the cornea 14, to the lens capsule 18 and to the retina 20.
- the IOLs according to the present invention represented in FIGS. 2, 8 and 14, generally designated by the reference numeral 12, are designed to be implanted preferably in the lens capsule 18 of an aphakic eye. .
- the IOL 12 has an optical portion 34 with an outer peripheral edge 36.
- Two or more, but preferably two, three or four equidistant haptic elements 38 are preferably formed integrally on the peripheral edge 36 of the optical portion 34.
- Each haptic element 38 has a similar shape to obtain a "helix" appearance to facilitate rotation and centering of IOL 12 during implantation inside the eye 10 and to obtain rotation of IOL 12 as described more in detail below.
- Each haptic element 38 is manufactured so as to have an internal portion 40 and an external portion 42.
- the internal portion 40 of each haptic element 38 comprises an enlarged fixing portion 44 preferably formed integrally and permanently connected with the external peripheral edge 36 of the optical portion 34.
- the enlarged fixing portion 44 of each haptic element 38 can be permanently fixed to the optical portion 34 by stapling, chemical polymerization or by other methods known to those skilled in the art.
- Each haptic element 38 also comprises on the external portion 42 a rounded free end 46 designed to avoid contact with the internal surfaces 48 of the lens capsule 18 of the aphakic eye 10.
- the haptic elements 38 are formed with elongated, arcuate central portions 50 which extend between the enlarged attachment portions 44 and the free ends 46. As best illustrated in Figures 5-7, 11-13 and 17-19, from the enlarged fixing portion 44 and all along the elongated central portion in in the form of an arc 50, the cross section of the haptic element 38 has a trapezoidal or, alternatively, rhomboid shape in order to obtain the desired characteristics for preventing OCP.
- the section of the haptic element 38 along lines 5/5, 6/6 and 7/7 are trapezoidal, the outer side 60 of the trapezoid having at its lower part an acute angle 52 and at its upper part an obtuse angle 71.
- the particular shape of the haptic elements 38 produces two effects: on the one hand thanks to the acute haptic edge 52, the migration of the capsular cells along the posterior surface 32 is blocked and on the other hand thanks to the obtuse external anterior haptic edge 71, rapid shuttering between the anterior surface 30 and the posterior surface 32 is possible.
- This closure comes from the phenomenon known as symphysis according to which, when the capsular bag has been emptied, the two walls 30 and 32 of said bag stick against one another. When they are so stick, there is no more migration of the capsular cells.
- the acute angle 52 is between 10 and 45 °.
- the haptic element 38 can be stable or its dimensions can vary from the enlarged fixing portion 44 and all along the central portion 50 on the plane 68-68 substantially perpendicular to the optical axis OA-OA.
- the haptic elements 38 with regular dimensions from the enlarged fixing portion 44 and all along the central portion 50 can be illustrated in the best way by FIGS. 6, 12 and 18 and by the dimensions which are proposed there. However, due to the increasing complexity of the embodiments having varying dimensions, they are discussed in more detail below.
- the width of the haptic element 38 gradually narrows on the plane 68-68 .
- the anterior surface 62 Approximately toward the enlarged attachment portion 44, the anterior surface 62 has a width of about 1.2 1.4 mm.
- the front surface 62 is preferably narrower by about 30 percent than the rear surface 64 which is preferably about 1.6 to 1.9 mm wide, as illustrated by the embodiments of the Figures 5, 11 and 17.
- the anterior surface 62 has a width of about 1.0 to 1.2 mm .
- the anterior surface 62 is preferably about 15 percent narrower than the posterior surface 64 which is preferably about 1.2 to 1.5 mm wide. As illustrated by the embodiments of FIGS. 7, 13 and 19, roughly towards the rounded free end 46, the anterior surface 62 and the posterior surface 64 have approximately the same width of approximately 0.5 to 1 , 0 mm.
- the haptic element 38 has a uniform thickness all along the plane 66-66 parallel to the optical axis OA-OA.
- the surface of the haptic internal edge 58 has a thickness of about 0.20 to 0.80 mm but, most preferably, about 0 , 34 to 0.48 mm.
- the surface of the internal haptic edge 58 may alternatively be angular rather than perpendicular to the anterior surface of the IOL 62 and to the posterior surface of the IOL 64 for forming an acute internal anterior haptic edge 79 along the anterior surface of the IOL 62.
- the surface of the external haptic edge 60 is angular rather than perpendicular to the anterior surface of IOL 62 and the posterior surface of IOL 64 to form an acute external posterior haptic edge 52 along the posterior surface of IOL 64.
- the width of the haptic elements 38 can decrease on plane 68-68 while the thickness on plane 66-66 remains homogeneous.
- LA LIO 12 is preferably produced with an optical portion 34 having a diameter of approximately 4.5 to 9.0 mm, but preferably approximately 5.0 to 6.0 mm and more precisely 6.0 mm and a thickness of about 0.2 mm to 1.0 mm, but preferably about 0.2 to 0.8 mm and more precisely 0.3 to 0.5 mm on the peripheral edge 36, as illustrated by the embodiment of FIG. 2.
- the peripheral edge 36 of the optical portion 34 is angled rather than perpendicular with respect to the anterior surface of the IOL 62 and to the posterior surface of the IOL 64. By thus angulating the peripheral edge 36, an acute posterior optical edge 54 is formed along the posterior surface of the IOL, as best illustrated in FIGS. 10 and 16.
- the peripheral edge 36 is arranged in the extension of the surface of the optical part 34.
- the haptic elements 38 extend from the optical portion 34 in the form of an arc in general and their overall length increases or decreases as a function of the diameter of the otic portion 34. When the diameter of the optical portion 34 increases, the overall length of the haptic elements 38 decreases. Likewise, when the diameter of the optical portion 34 decreases, the overall length of the haptic elements 38 increases.
- the haptic elements are formed to have a length of about 2.6 to 6.0 mm, but preferably about 3.4 to 5.5 mm and, more specifically, about 4.8 mm, measured between the center of the enlarged fixing portion 44 and the center of the rounded free end 46.
- the IOL preferably measures between 1 1 and 13 mm in total, between the contact area 72 and the opposite contact area 72.
- the IOL 12 is preferably positioned with the contact zones 72 of the external posterior haptic edges 52 in contact with the internal surfaces 48 of the lens capsule 18.
- the haptic elements 38 of the IOL 12 are inclined outward to maintain constant contact between the contact zones 72 and the internal surfaces 48.
- the central portions 50 of the haptic elements 38 are slightly bent inwards on the plane 68-68.
- the central portions 50 therefore flex under the compressive forces because they have a reduced width compared to that of the enlarged fixing portions 44.
- the haptic elements 38 bend at the central portions 50, the surfaces of the internal haptic edge 58 approach the external peripheral edge 36.
- the external posterior haptic edges 52 preferably with the posterior optical edge 54 of the IOL 12 come into contact with the internal surfaces 48 of the lens capsule 18 to prevent OCP.
- the outer posterior haptic edges 52 and the posterior optical edge 54 prevent OCP by serving as a barrier to cell migration and proliferation inside the lens 18. Therefore, when the IOL 12 is used as a refractive lens, obtains a stable and reliable refractive correction.
- Materials suitable for the production of IOLs 12 include, but are not limited to, pliable or compressible materials such as silicone polymers, hydrocarbon and fluorinated hydrocarbon polymers, soft acrylic polymers without water content, with a low water content and with a high water content, polyesters, polyamides, polyurethane, silicone polymers with hydrophilic monomer units, polysiloxane elastomers containing fluorine and combinations thereof.
- the preferred material for the production of LIO 12 according to the present invention is a hydrophilic or hydrophobic acrylic material such as those known to those skilled in the art.
- Poly (hydroxyethyl methacrylate-co-hydroxyhexyl methacrylate) (poly (HEMA-co-HOHEXMA) and methyl methaciylate-hydroxyethyl methacrylate (MMA-HEMA) are the preferred hydrophilic acrylic materials useful for the manufacture of LIO 12 because of the contents of equilibrium water of between about 17 and about 27 percent by weight and the high refractive index of about 1.46 or more, which is higher than that of the aqueous humor of the eye, it i.e. 1.33.
- a high refractive index is a desirable characteristic for the production of IOLs to impart high optical power with minimal optical thickness. By using a material with a high refractive index, visual acuity defects can be corrected using a thinner IOL.
- Poly (HEMA-co-HOHEXMA) and MMA-HEMA are also desirable materials for the production of LIO 12 because of their mechanical strength which is suitable for withstanding considerable physical manipulation.
- Poly (HEMA-co-HOHEXMA) and MMA-HEMA also have desirable memory properties suitable for the use of IOLs.
- IOLs made from a material with good memory properties such as poly (HEMA-co-HOHEXMA) and MMA-HEMA unfold in an eye in a controlled rather than explosive way to take their predetermined shape. Explosive unfolding of IOLs is undesirable due to the potential damage to delicate tissue inside the eye.
- Poly (HEMA-co-HOHEXMA) and MMA-HEMA also have non-deformability in the eye.
- the LIO 12 can similarly be made from a variety of materials with varying physical characteristics.
- the IOLs 12 can be manufactured to have an optical portion 34 made of a hydrophilic acrylic material with a high refractive index, haptic elements 38 made of a more rigid material than that of the optical portion 34 and contact zones 72 made of the same material as that of the optical portion 34 or of another material having a lower refractive index and a higher glass transition temperature.
- the teachings of the present invention are preferably applied to soft or pliable IOLs made of a pliable or compressible material, it is also the same for lenses harder, less flexible made in a relatively rigid material such as polymethyl methyl acrylate (PMMA) having flexible haptics made either in the same material or in a different material.
- PMMA polymethyl methyl acrylate
- the optical portion 34 of the IOL 12 can be a lens with positive power between 0 and approximately +40 diopters or a lens with negative power between 0 and approximately -30 diopters.
- the optical portion 34 can be biconvex, piano-convex, piano-concave, biconcave or concave-convex (meniscus) depending on the power necessary to obtain the central and peripheral thickness for efficient handling.
- the optical portion 34 of the IOL 12 can be formed with a brightness reduction zone 74 having a width of about 0.25 to 0.75 mm but preferably about 0.3 to 0.6 mm and most preferably 0.5 mm adjacent to the outer peripheral edge 36 for reduced brightness when the outer peripheral edge 36 of the IOL 12 is struck by the light which enters the eye 10 in high light or at other times when pupil 76 is dilated.
- the brightness reduction zone 74 is typically made of the same material as that of the optical portion 34, but it can be opaque, colored or conventionally designed to block or scatter light in the plane having the optical axis OA-OA.
- LIO 12 is preferably manufactured by first producing discs of one or more materials from one or more selected materials as described in US Pat. Nos. 5,217,491 and 5,326,506. The IOL 12 can then be machined from the material discs in a conventional manner. Once machined, the IOL 12 can be polished, cleaned, sterilized and packaged using a conventional process known to those skilled in the art.
- the IOL 12 is used in the eye 10 by making an incision in the cornea 14 and by inserting the IOL 12 in the posterior chamber 24 and by closing the incision according to the methods known to those skilled in the art.
- IOL 12 can preferably be used in the eye 10 by making an incision in the cornea 14 and the lens capsule 18, extracting the natural lens, inserting the IOL 12 into the lens capsule 18 and closing the incision according to methods known to those skilled in the art.
- the IOL 12 according to the present invention provides a refractive lens suitable for use in the lens capsule 18 or in the posterior chamber 24, but preferably in the lens capsule 18 because of its OCP preventive characteristics.
- the IOL 12 has haptic elements 38 of similar shape to minimize or eliminate the decentering of the LIO 12 and the distortion of vision. The similar shape of the haptic elements 38 similarly allows the rotation of the IOL 12 for better positioning and better adjustment inside the lens capsule 18.
- This better fitting inside the lens capsule 18 has an advantage because one or a few lens sizes suitably fit most eye dimensions 10.
- a "universal" lens such as that according to the present invention, clinical risks for patients are minimized by poorly dimensioned lenses.
- the need for manufacturers to produce many sizes of IOLs to adjust them to the many dimensions of eyes is eliminated, thereby reducing the costs of production of storage which result therefrom.
- IOL 12 also benefit from IOL 12 in that they save time by eliminating the need to determine the size of each patient's eye and the costs associated with maintaining large stocks of lenses of various sizes.
- Another characteristic of the IOL 12 illustrated by the embodiment of FIG. 14 is one or more, but preferably between one and three surface edge grooves 78.
- the surface edge grooves 78 allow more complete surgical irrigation, and thus better cleaning of the viscoelastic residues and residues of crystalline cortex inside the lens capsule 18.
- a fluid is circulated inside the lens capsule 18 to remove viscoelastic and various other residues.
- the edge surface grooves 78 improve the circulation of the fluid by providing a clear path for the passage of the fluid. We therefore proceed to a more complete cleaning inside the lens capsule 18 using this reinforced fluid circulation.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002358867A AU2002358867B2 (en) | 2001-10-31 | 2002-10-31 | Intraocular lenses provided with angled edges to prevent posterior capsular opacification |
CA002464705A CA2464705A1 (fr) | 2001-10-31 | 2002-10-31 | Lentilles intraoculaires munies de bords angules pour prevenir une opacification capsulaire posterieure |
US10/432,903 US20040042073A1 (en) | 2001-10-31 | 2002-10-31 | Intraocular lenses provided with angled edges to prevent posterior capsular opacification |
EP02793203A EP1443875A1 (fr) | 2001-10-31 | 2002-10-31 | Lentilles intraoculaires munies de bords angules pour prevenir une opacification capsulaire posterieure |
JP2003539573A JP2005507286A (ja) | 2001-10-31 | 2002-10-31 | 後嚢の不透明化を防止するための角度のついた縁を有する眼内レンズ |
HK05102335A HK1069758A1 (en) | 2001-10-31 | 2005-03-17 | Intraocular lenses provided with angular edges to prevent posterior |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/14100 | 2001-10-31 | ||
FR0114100A FR2831423B1 (fr) | 2001-10-31 | 2001-10-31 | Lentilles intraoculaires munies de rebords anguleux afin d'eviter une opacification capsulaire posterieure |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003037225A1 true WO2003037225A1 (fr) | 2003-05-08 |
Family
ID=8868933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/003754 WO2003037225A1 (fr) | 2001-10-31 | 2002-10-31 | Lentilles intraoculaires munies de bords angules pour prevenir une opacification capsulaire posterieure |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040042073A1 (fr) |
EP (1) | EP1443875A1 (fr) |
JP (1) | JP2005507286A (fr) |
KR (1) | KR20050042034A (fr) |
CN (1) | CN100339058C (fr) |
AR (1) | AR037173A1 (fr) |
AU (1) | AU2002358867B2 (fr) |
CA (1) | CA2464705A1 (fr) |
FR (1) | FR2831423B1 (fr) |
HK (1) | HK1069758A1 (fr) |
WO (1) | WO2003037225A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002372A1 (fr) * | 2002-06-27 | 2004-01-08 | Bausch & Lomb Incorporated | Cristallin artificiel |
WO2008036671A1 (fr) | 2006-09-21 | 2008-03-27 | Advanced Medical Optics, Inc. | Cristallins artificiels pour gérer l'éblouissement, l'adhérence et la migration cellulaire |
FR2922096A1 (fr) * | 2007-10-16 | 2009-04-17 | Ioltechnologie Production Sarl | Lentille intraoculaire pour sac capsulaire |
US8357196B2 (en) | 2009-11-18 | 2013-01-22 | Abbott Medical Optics Inc. | Mark for intraocular lenses |
US9603702B2 (en) | 2006-09-21 | 2017-03-28 | Abbott Medical Optics Inc. | Intraocular lenses for managing glare, adhesion, and cell migration |
EP3672523A4 (fr) * | 2017-09-20 | 2021-05-19 | Clearsight, LLC | Lentilles intraoculaires monobloc et leurs procédés de fabrication |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004025305A1 (de) * | 2004-05-19 | 2005-12-08 | Humanoptics Ag | Akkommodierbare Intraokularlinse |
US8167940B2 (en) * | 2008-05-06 | 2012-05-01 | Novartis Ag | Aspheric toric intraocular lens |
US9943402B2 (en) | 2008-11-20 | 2018-04-17 | Insight Innovations, Llc | Micropatterned intraocular implant |
WO2010059214A2 (fr) * | 2008-11-20 | 2010-05-27 | Insight Innovations, Llc | Système d'implant intraoculaire biodégradable et biocompatible |
US20120232649A1 (en) | 2008-11-20 | 2012-09-13 | Insight Innovations, Llc | Intraocular Lens Cell Migration Inhibition System |
JP5695035B2 (ja) | 2009-06-03 | 2015-04-01 | フォーサイト・ビジョン5・インコーポレイテッドForsight Vision5,Inc. | 前眼部薬物供給 |
PH12012501074A1 (en) * | 2009-12-01 | 2013-02-04 | Alcon Res Ltd | Intraocular lens having edge configured to reduce posterior capsule opacification |
CN102247222B (zh) * | 2010-05-17 | 2015-09-09 | 爱博诺德(北京)医疗科技有限公司 | 软性人工晶体装置 |
JP5989780B2 (ja) | 2011-09-14 | 2016-09-07 | フォーサイト・ビジョン5・インコーポレイテッドForsight Vision5,Inc. | 眼挿入装置および方法 |
US9999499B2 (en) * | 2012-09-04 | 2018-06-19 | Carl Zeiss Meditec Production, LLC | Preloaded intraocular lens (IOL) system and method |
DK2911623T3 (da) | 2012-10-26 | 2019-10-28 | Forsight Vision5 Inc | Oftalmisk system til langvarig frigivelse af lægemiddel til øjet |
JP6295606B2 (ja) * | 2013-10-31 | 2018-03-20 | 株式会社ニデック | 眼内レンズ |
WO2016168141A1 (fr) | 2015-04-13 | 2016-10-20 | Forsight Vision5, Inc. | Composition d'insert oculaire d'agent pharmaceutiquement actif cristallin ou semi-cristallin |
CN106901871B (zh) * | 2015-12-23 | 2021-08-24 | 爱博诺德(北京)医疗科技股份有限公司 | 具有一个或多个附加部分的人工晶状体 |
CN110916850A (zh) * | 2019-11-21 | 2020-03-27 | 浙江大学 | 一种后表面分区修饰的人工晶状体及其制备方法 |
US11759309B2 (en) | 2020-04-29 | 2023-09-19 | Long Bridge Medical, Inc. | Devices to support and position an intraocular lens within the eye and methods of use |
CN112120830A (zh) * | 2020-10-10 | 2020-12-25 | 上海市同济医院 | 一种巩膜自固定型人工晶体 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215468A2 (fr) * | 1985-09-14 | 1987-03-25 | Fromberg, Gunther, Dr. | Lentille artificielle pour implantation dans l'oeil |
WO1988009950A1 (fr) * | 1987-06-01 | 1988-12-15 | Valdemar Portney | Lentille ophtalmique multifocale |
EP0398813A1 (fr) * | 1989-05-19 | 1990-11-22 | ESSILOR INTERNATIONAL Compagnie Générale d'Optique | Composant optique, tel qu'implant intra-oculaire ou lentille de contact, propre à la correction de la vision d'un individu |
WO2001034067A1 (fr) * | 1999-11-05 | 2001-05-17 | Bausch & Lomb Incorporated. | Systeme de lentille intraocculaire |
WO2001037762A1 (fr) * | 1999-11-24 | 2001-05-31 | Allergan Sales, Inc. | Cristallin artificiel permettant d'inhiber la croissance cellulaire et de reduire l'eblouissement |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US521749A (en) | 1894-06-19 | Machine for making cigarettes | ||
US5002568A (en) * | 1986-10-06 | 1991-03-26 | Surgidev Corporation | Intraocular lens |
US5217491A (en) | 1990-12-27 | 1993-06-08 | American Cyanamid Company | Composite intraocular lens |
DE69220596T2 (de) * | 1991-04-04 | 1998-02-05 | Menicon Co Ltd | Vorrichtung zum Verhindern von Sekundärkatarakt |
US6228115B1 (en) * | 1998-11-05 | 2001-05-08 | Bausch & Lomb Surgical, Inc. | Intraocular lenses with improved axial stability |
US20030060881A1 (en) * | 1999-04-30 | 2003-03-27 | Advanced Medical Optics, Inc. | Intraocular lens combinations |
FR2792825B1 (fr) * | 1999-04-30 | 2001-06-29 | Ioltechnologie Production | Implant de chambre posterieure aphake chez le myope fort |
FR2795944B1 (fr) * | 1999-07-08 | 2001-11-02 | Corneal Ind | Implant intraoculaire |
US20020087210A1 (en) * | 1999-09-02 | 2002-07-04 | Donald Carrol Stenger | Intraocular |
US6352542B1 (en) * | 2000-03-08 | 2002-03-05 | Michael E. Snyder | Intraocular lens with improved haptic and method of implanting same |
US6425917B1 (en) * | 2000-05-12 | 2002-07-30 | Tekia | Phakic iol film frame |
US20030055499A1 (en) * | 2001-09-14 | 2003-03-20 | Nguyen Tuan Anh | Low profile intraocular lenses |
-
2001
- 2001-10-31 FR FR0114100A patent/FR2831423B1/fr not_active Expired - Fee Related
-
2002
- 2002-10-31 JP JP2003539573A patent/JP2005507286A/ja not_active Withdrawn
- 2002-10-31 CA CA002464705A patent/CA2464705A1/fr not_active Abandoned
- 2002-10-31 EP EP02793203A patent/EP1443875A1/fr not_active Withdrawn
- 2002-10-31 KR KR1020047006527A patent/KR20050042034A/ko not_active Ceased
- 2002-10-31 CN CNB028218485A patent/CN100339058C/zh not_active Expired - Fee Related
- 2002-10-31 WO PCT/FR2002/003754 patent/WO2003037225A1/fr active Application Filing
- 2002-10-31 US US10/432,903 patent/US20040042073A1/en not_active Abandoned
- 2002-10-31 AU AU2002358867A patent/AU2002358867B2/en not_active Ceased
- 2002-10-31 AR ARP020104146A patent/AR037173A1/es not_active Application Discontinuation
-
2005
- 2005-03-17 HK HK05102335A patent/HK1069758A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215468A2 (fr) * | 1985-09-14 | 1987-03-25 | Fromberg, Gunther, Dr. | Lentille artificielle pour implantation dans l'oeil |
WO1988009950A1 (fr) * | 1987-06-01 | 1988-12-15 | Valdemar Portney | Lentille ophtalmique multifocale |
EP0398813A1 (fr) * | 1989-05-19 | 1990-11-22 | ESSILOR INTERNATIONAL Compagnie Générale d'Optique | Composant optique, tel qu'implant intra-oculaire ou lentille de contact, propre à la correction de la vision d'un individu |
WO2001034067A1 (fr) * | 1999-11-05 | 2001-05-17 | Bausch & Lomb Incorporated. | Systeme de lentille intraocculaire |
WO2001037762A1 (fr) * | 1999-11-24 | 2001-05-31 | Allergan Sales, Inc. | Cristallin artificiel permettant d'inhiber la croissance cellulaire et de reduire l'eblouissement |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002372A1 (fr) * | 2002-06-27 | 2004-01-08 | Bausch & Lomb Incorporated | Cristallin artificiel |
WO2008036671A1 (fr) | 2006-09-21 | 2008-03-27 | Advanced Medical Optics, Inc. | Cristallins artificiels pour gérer l'éblouissement, l'adhérence et la migration cellulaire |
US9603702B2 (en) | 2006-09-21 | 2017-03-28 | Abbott Medical Optics Inc. | Intraocular lenses for managing glare, adhesion, and cell migration |
FR2922096A1 (fr) * | 2007-10-16 | 2009-04-17 | Ioltechnologie Production Sarl | Lentille intraoculaire pour sac capsulaire |
WO2009087302A3 (fr) * | 2007-10-16 | 2009-09-24 | Ioltechnologie-Production | Lentille intraoculaire pour sac capsulaire |
US8734510B2 (en) | 2007-10-16 | 2014-05-27 | Carl Zeiss Meditec Sas | Intraocular lens for capsular bag |
US8357196B2 (en) | 2009-11-18 | 2013-01-22 | Abbott Medical Optics Inc. | Mark for intraocular lenses |
EP3672523A4 (fr) * | 2017-09-20 | 2021-05-19 | Clearsight, LLC | Lentilles intraoculaires monobloc et leurs procédés de fabrication |
Also Published As
Publication number | Publication date |
---|---|
FR2831423A1 (fr) | 2003-05-02 |
HK1069758A1 (en) | 2005-06-03 |
KR20050042034A (ko) | 2005-05-04 |
AR037173A1 (es) | 2004-10-27 |
EP1443875A1 (fr) | 2004-08-11 |
CN100339058C (zh) | 2007-09-26 |
JP2005507286A (ja) | 2005-03-17 |
US20040042073A1 (en) | 2004-03-04 |
FR2831423B1 (fr) | 2004-10-15 |
CN1582137A (zh) | 2005-02-16 |
AU2002358867B2 (en) | 2008-03-06 |
CA2464705A1 (fr) | 2003-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003037225A1 (fr) | Lentilles intraoculaires munies de bords angules pour prevenir une opacification capsulaire posterieure | |
AU775462B2 (en) | Intraocular lenses | |
AU775571B2 (en) | Intraocular lenses | |
EP1200019B1 (fr) | Lentilles intraoculaires | |
CA2430005C (fr) | Lentille intra-oculaire fixee sur l'iris | |
US9259308B2 (en) | Foldable intraocular lens and method of making | |
AU774948B2 (en) | Intraocular lens system | |
JP2003533274A (ja) | 虹彩固定型の折り畳み可能な眼内レンズ | |
JP2003530202A (ja) | 眼内レンズ | |
CA2382278A1 (fr) | Lentilles intraoculaires | |
CA2348919A1 (fr) | Lentille intra-oculaire flexible | |
AU2001259541A1 (en) | Injectable iris fixated intraocular lenses | |
FR2569557A1 (fr) | Lentilles artificielles intra-oculaires ameliorees | |
AU2004229073B2 (en) | Intraocular lenses | |
FR2899093A1 (fr) | Lentille intraoculaire refractive de chambre anterieure, notamment pour oeil phaque. | |
FR3067591A1 (fr) | Implant intraoculaire pour le traitement de la cataracte chez l'homme et l'animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10432903 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002793203 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2464705 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003539573 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028218485 Country of ref document: CN Ref document number: 1020047006527 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002358867 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002793203 Country of ref document: EP |